Zenagamtide是一种新型的长效单分子GLP-1和胰淀素受体激动剂不会延缓胃排空.pdf

1、1Novo Nordisk A/S,Sborg,Denmark;2Novo Nordisk Service Centre India Private Ltd,Bangalore,India;3Altasciences Inc.,Montreal,QC,Canada.This study was sponsored by Novo Nordisk A/S and is registered with ClinicalTrials.gov(NCT06461039).Medical writing support was provided by Donna Kennedy,PhD,of Apollo

2、,OPEN Health Communications,and funded by Novo Nordisk A/S,in accordance with Good Publication Practice(GPP)guidelines(ismpp.org/gpp-2022).MBNG is an employee of Novo Nordisk A/S.Presented at the 33rd European Congress on Obesity(ECO),1215 May 2026,Istanbul,Trkiye.References:(1)Sanyal AJ et al.N Eng

3、l J Med 2025;392:20892099;(2)Perkovic V et al.N Engl J Med;2024;391:109121;(3)Wilding JPH et al.N Engl J Med 2021;384:9891002;(4)Lincoff AM et al.N Engl J Med 2023;389:22212232;(5)Kosiborod MN et al.N Engl J Med 2023;389:10691084;(6)Lutz TA.Appetite 2022;172:105965;(7)Gasiorek A et al.Lancet 2025;40

4、6:135148;(8)Dahl K et al.Lancet 2025;406:149162;(9)Kuhre RE et al.EBioMedicine 2025;118;105862;(10)Lutz TA.Neuropharmacology 2025;278:110587;(11)Friedrichsen M et al.Diabetes Obes Metab 2021;23:754762.Zenagamtide,a novel,long-acting,unimolecular GLP-1 and amylin receptor agonist,does not delay gastr

5、ic emptyingMaria B.N.Gabe1,Ruben Duque do Vale1,Swathi Gopal2,Tobias Karlsson1,Gaetano Morelli3,Anne Flint1PO4.219https:/ QR code or visit the website below for:PosterPoster+slidesAim To evaluate the effect of oral and subcutaneous(s.c.)zenagamtide on gastric emptying.Introduction Glucagon-like pept

6、ide-1(GLP-1)receptor agonists have demonstrated clinically significant reductions in body weight and additional benefits,including reductions in cardiovascular risk and improvements in outcomes in people with heart failure,chronic kidney disease and metabolic dysfunction-associated steatohepatitis.1